Skip to main content
Erschienen in: BMC Complementary Medicine and Therapies 1/2013

Open Access 01.12.2013 | Research article

In vitro and in vivo antibacterial activities of cranberry press cake extracts alone or in combination with β-lactams against Staphylococcus aureus

verfasst von: Moussa S Diarra, Glenn Block, Heidi Rempel, B Dave Oomah, Judy Harrison, Jason McCallum, Simon Boulanger, Éric Brouillette, Mariza Gattuso, François Malouin

Erschienen in: BMC Complementary Medicine and Therapies | Ausgabe 1/2013

Abstract

Background

Cranberry fruits possess many biological activities partly due to their various phenolic compounds; however the underlying modes of action are poorly understood. We studied the effect of cranberry fruit extracts on the gene expression of Staphylococcus aureus to identify specific cellular processes involved in the antibacterial action.

Methods

Transcriptional profiles of four S. aureus strains grown in broth supplemented or not with 2 mg/ml of a commercial cranberry preparation (Nutricran®90) were compared using DNA arrays to reveal gene modulations serving as markers for biological activity. Ethanol extracted pressed cakes from fresh fruits also produced various fractions and their effects on marker genes were demonstrated by qPCR. Minimal inhibitory concentrations (MICs) of the most effective cranberry fraction (FC111) were determined against multiple S. aureus strains and drug interactions with β-lactam antibiotics were also evaluated. Incorporation assays with [3H]-radiolabeled precursors were performed to evaluate the effect of FC111 on DNA, RNA, peptidoglycan (PG) and protein biosynthesis.

Results

Treatment of S. aureus with Nutricran®90 or FC111 revealed a transcriptional signature typical of PG-acting antibiotics (up-regulation of genes vraR/S, murZ, lytM, pbp2, sgtB, fmt). The effect of FC111 on PG was confirmed by the marked inhibition of incorporation of D-[3H]alanine. The combination of β-lactams and FC111 in checkerboard assays revealed a synergistic activity against S. aureus including strain MRSA COL, which showed a 512-fold drop of amoxicillin MIC in the presence of FC111 at MIC/8. Finally, a therapeutic proof of concept was established in a mouse mastitis model of infection. S. aureus-infected mammary glands were treated with amoxicillin, FC111 or a combination of both; only the combination significantly reduced bacterial counts from infected glands (P<0.05) compared to the untreated mice.

Conclusions

The cranberry fraction FC111 affects PG synthesis of S. aureus and acts in synergy with β-lactam antibiotics. Such a fraction easily obtained from poorly exploited press-cake residues, may find interesting applications in the agri-food sector and help reduce antibiotic usage in animal food production.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1472-6882-13-90) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests. Also note that Decas Botanical Synergies, the manufacturers of NC90, played no role in the design, implementation, analysis, or financing of this study.

Authors’ contributions

SB, EB, MG, GB, HR, JH and JM carried out the experiments. MSD, BDO, SB, EB, MG, JH and FM designed and conceived the study. MSD, DBO, SB, JH and FM wrote the paper. All authors read and approved the final manuscript.

Background

Staphylococcus aureus is an opportunistic pathogen responsible for many infectious diseases in humans and animals [1]. This bacterium is among the most prevalent causes of food poisoning gastroenteritis worldwide [2], as well as a leading cause of intramammary infections (gland inflammation, mastitis) in cows, milk quality and yield reduction, and major economic losses for the dairy industry [3]. In poultry, S. aureus induces infections having a major impact on the fertility and productivity of a breeder flock. Infections by S. aureus can occur in the joints or as a generalized infection (septicemia). Manifestations with more important economic consequences include synovitis with arthritis, osteomyelitis, and dermatitis [4]. Early efficient treatment of infection is paramount to avoid development of a chronic infection, acute infection resulting in irreversible tissue necrosis, or exacerbation leading to organ failure [5]. However, treating S. aureus infections becomes increasingly challenging due to its capacity to develop enhanced antibiotic resistance. Such resistance has developed due to the protective effects provided by biofilm production [6], chromosomal mutations, the acquisition or expression of various antibiotic resistance genes including those encoding low-affinity penicillin-binding proteins (PBPs) involved in cell wall peptidoglycan biosynthesis, and efflux pumps [7, 8].
The first report of a penicillin-resistant S. aureus occurred in the 1940s, followed by the emergence of methicillin-resistant S. aureus (MRSA) strains, which possess the low-affinity PBP2A encoded by the mecA gene. These now multi-resistant strains can induce various nosocomial and community-associated infections [9]. The emergence and widespread occurrence of hospital and community acquired MRSA as well as livestock-associated MRSA resulted from antibiotic selection pressure and horizontal and vertical gene transfers [10]. Concerning livestock, a high prevalence of MRSA was reported in pigs and pig farmers [11], and in Europe, MRSA strains found primarily in pigs are now a leading cause of community-associated MRSA infections in humans [12]. Similarly, the recent emergence of bovine MRSA is also a concern since these strains are transmittable to humans [13, 14]. The occurrence of MRSA among companion and food-producing animals and possible impact on human health has been reviewed by Petinaki and Spiliopoulou [15]. New research approaches, novel sources of antibiotic compounds and discovery of original microbial cell targets need to be developed in order to overcome multi-resistant bacteria such as MRSA.
The urge to bring forth novel antibiotic molecules hastened the investigation of the perspectives offered by plants. As such, many studies on berry fruits have shown the presence of large scale bioactive compounds such as cancer cell growth inhibitors, antimicrobial molecules, and antioxidants [1618]. Cranberry (Vaccinium macrocarpon Ait) is one of the berries having the most potent antimicrobial effects against several human pathogens. We showed a lower mortality rate in chickens fed a commercial cranberry fruit extract (Nutricran®90) in feed compared to a non-supplemented control diet and that feeding birds diets containing cranberry fruit extract was effective in influencing the populations of bacteria such as Enterococcus[19]. The mechanism underlining this observation is unknown, however our study suggests that cranberry extract causes a shift in the bacterial population in the intestinal tract. Water-soluble phenolic compounds of cranberry juice, such as flavonoids (ex: anthocyanins and flavonols), have higher antimicrobial activities against foodborne pathogens than apolar phenolic compounds like polymeric tannins [16]. The bacterial cell wall and cellular membranes have been identified as targets of cranberry extracts on Gram-negative and Gram-positive foodborne pathogens like Escherichia coli O157:H7 and S. aureus[20], however, information is limited regarding the mechanism of action of cranberry on bacteria.
In this work, we have investigated the effect of Nutricran®90, and three extracts obtained from fresh cranberry fruits, on the transcriptional profiles of S. aureus, to provide insights on the antibacterial modes of action of such preparations. We identified a transcriptional signature that reveals inhibition of bacterial peptidoglycan biosynthesis. We also demonstrated the bactericidal effect of a combination of a cranberry extract and β-lactams in vitro, and the therapeutic usefulness of such a synergistic combination of agents in a mouse mastitis model of infection.

Methods

Bacterial strains and growth conditions

The antibiotic susceptibility testing reference strain Staphylococcus aureus ATCC 29213, the sequenced MRSA strains COL and N315, as well as the bovine mastitis isolates: Newbould (ATCC 29740), SHY97-4320 and SHY97-3906, were used in this study. Strains SHY97-4320 and SHY97-3906 were isolated from clinical mastitis and were previously described [21]. Bacteria stocks were kept frozen at −80°C and grown on Mueller Hinton agar or Cation adjusted Muller Hinton broth (CAMHB, Becton Dickinson, Mississauga, ON, Canada). Viable bacterial counts (CFU) were determined on Tryptic Soy agar (TSA, Becton Dickinson).

Cranberry products, antibiotics and chemical reagents

A commercial cranberry product, Nutricran®90 (NC90), was obtained from Decas Botanical Synergies (Wareham, MA, USA). The NC90 contained at least 88% carbohydrates, 30% organic acids, 2 to 3.8% total phenolic compounds, 0.3 to 1% anthocyanins, 0.8 to 1.5% proanthocyanidins, 300 to 435 μg/g of quercetin, and was 100% soluble in water as described by the manufacturer. Laboratory and pilot-scale preparations of extracts were performed with fresh Ben Lear cranberries obtained from a local farm (Agassiz, British Columbia, Canada) or from Ocean Spray (Langley, BC, Canada) as described previously [17]. Chloramphenicol, oxacillin, amoxicillin, norfloxacin, rifampicin and vancomycin were purchased from Sigma Aldrich (Oakville, Ontario, Canada).

Preparation of cranberry press cake extracts

Laboratory-scale fraction were obtained from 2 Kg of fresh fruits which were hammer milled through 1 cm holes then pressed in a miniature rack and cloth press at 3000 psi for 10 min to obtain juice and press cake (PC). Triplicate allotments of PC (90 ± 5 g) were placed into screw cap polyethylene centrifuge containers and covered with 95% ethanol and kept at room temperature for 48 h. Triplicate extracts were pooled, dried by rotary evaporation to remove the ethanol (Büchi rotavapor R, Brinkmann Instruments Canada Corp.; 30°C, speed 5–7, full vacuum (−25kPa; Büchi Vac V-500) with condenser temperature of 0°C), and freeze dried (Virtis 50-SRC, Gardiner, NY, USA; condenser at −56°C; vacuum at −100 milli-Torr; shelf at 25°C) to obtain fraction FC111. Replicate PC mashes were used for one and two other extractions with 95% ethanol, and the soluble fractions were freeze dried (fractions FC121 and FC131, respectively). Pilot-scale extraction procedures were previously described [17]. In brief, the fresh cranberries were pressed in a hydraulic rack and cloth press and the juice was separated from the PC. Following this step, the PC was covered with 95% ethanol for 24 h. Then, the crushed cranberries were decanted and the soluble fraction was refrigerated at 1°C (fraction FC111).
Phenolic acids, anthocyanins, flavonols and tartaric esters were determined by the method of Oomah et al. [22]. Antioxidant activity was measured through oxygen radical absorbance capacity (ORAC), as described previously [23]. The polyphenolics and antioxidant activities of the fresh cranberry fruit fractions obtained by pilot-scale ethanol extraction of the PC was previously reported [17]. As described, PC extracts including FC111 showed three to four times the phenolic acid, tartaric ester contents and antioxidant activities, as well as five to 10 times the flavonols and anthocyanins of their respective juice powders [17]. There was good similarity between the amounts of measured chemical constituents of laboratory- and pilot-scale preparations, as well as their antimicrobial activity (see result section).

Antibiotic susceptibility testing and synergy studies

Minimal inhibitory concentrations (MICs) of antibiotics and cranberry extracts were determined by a broth microdilution technique, following the recommendations of the Clinical and Laboratory Standards Institute [24]. A checkerboard protocol [25] was conducted by a broth microdilution method similar to that used for standard MIC determinations to evaluate the effect of varying concentrations of cranberry extracts on the activity of known antibiotics against S. aureus strains. The fractional inhibitory concentration (FIC) indices were calculated as follow: FIC index = FICA + FICB = A/MICA+ B/MICB, where A and B are MICs of compounds A and B in combination, MICA and MICB are the MICs of compound A and compound B alone and FICA and FICB are the FICs of compound A and of compound B. Indifference for drug interactions or an additive effect is demonstrated if the FIC index is >0.5-4, a synergy if the FIC index is ≤ 0.5, whereas an antagonistic effect is represented by a FIC index of >4 [26].

Time-kill experiments

Time-kill experiments were performed to observe the bactericidal effect (i.e., a 3 log10 reduction in CFU/mL) of cranberry extracts alone or in combination with sub-inhibitory concentrations (sub-MICs) of traditional antibiotics. The CAMHB medium was inoculated with S. aureus at ~105-106 CFU/mL and grown at 35°C, with shaking (225 rpm) in the absence or presence of tested agents at the specified concentrations (see the figure legends). At several time points, bacteria were sampled, serially diluted and plated on TSA for CFU determinations.

Transcriptional profiles

The modulation of transcriptional profiles of S. aureus strains ATCC 29213, MRSA N315, SHY97-4320 and SHY97-3406 by the cranberry product NC90 was first evaluated by exploratory transcriptional profiling experiments using a sub-genomic array as described previously (in detail) [27, 28]. Bacteria (~107-108 CFU/mL) were exposed to NC90 at the MIC (2 mg/mL) for 30 min in CAMHB. Culture samples (~108 cells) were treated with RNAprotect (Qiagen, Mississauga, ON, Canada) for at least 10 min. Bacterial pellets were then suspended in 100 μL of TE buffer containing 200 μg/mL lysostaphin and incubated at room temperature for 1 h. RNA was extracted using the RNeasy Mini Kit and treated with the RNAse-free DNAse set (Qiagen). Total RNA (2.5 μg) and 1 μL of the appropriate RNA spike from Lucidea Universal Scorecard (GE Healthcare Life Sciences, Baie D’Urfé, QC, Canada) was reverse transcribed using 5 μg of random hexamers, a dNTP mix, 5-[3-aminoallyl]-2-dUTP and the Superscript II RT (Invitrogen, Life Technologies Inc., Burlington, ON, Canada). The amino-modified cDNA was purified and labeled with NHS-Cy3 (untreated control) and -Cy5 (bioactive agent test) prior to hybridization on GAPS II slides (Corning, NY, USA). The probes (200 pmol, ≥8% incorporation) were suspended in 18.5 μL of hybridization buffer (5X SSC, 0.1% SDS, 25% formamide, 100 μg/ml mouse COT1 DNA (Invitrogen)). The prehybridization, hybridization and washing steps were done as prescribed for Corning Gaps II Slides. Hybridization signals for each spot were quantified with the ScanArrayExpress Microarray Scanner and the ScanArrayExpress software V 2.2.0.0022 (Perkin Elmer, Wellesley, MA, USA). Intensity of each dye was adjusted using the signal of the control spots from Lucidea Universal Scorecard and data were submitted to the Lowess normalization. Only signals showing intensity three times above the background were analyzed as described previously [18, 27]. Expression ratios (Cy5 [treated]/Cy3 [untreated control]) were represented in log2. Only log2 ratios with a minimum mean of ≥2.0 (or ≤ −2.0) obtained for at least two of the four S. aureus strains tested were considered. Data represent the average of triplicate spots from duplicate independent experiments for each of the four tested S. aureus strains. The modulation of expression of marker genes providing transcriptional signatures was thereafter confirmed by qPCR analyses.

Quantitative PCR (qPCR)

Transcriptional modulations induced by cranberry fractions and observed by using exploratory microarrays were confirmed by qPCR for a selection of marker genes and strains. Additional RNAs, from three independent bacterial cultures and prepared as described above, were obtained for qPCR analyses. The qPCR assays using SYBR green (Invitrogen) and the JumpStart Taq DNA Polymerase (Sigma) were performed as described previously [27] for the marker vraS, sgtB, murZ, mrsA, lytM and mntB genes indicative of a cell wall stress [29, 30]. The relative expression ratios were calculated using the cycle threshold (C t) of the untreated culture (no-bioactive agent control) and that of the housekeeping gyrA gene [n-fold expression = 2-ΔΔC t, where ΔΔC t = ΔC t (treated culture)/ΔC t (untreated culture) and ΔC t represents the difference between the C t of the gene studied and the C t of gyrA]. The sequences of primers for qPCR were: gyrA-forward 5-CATTGCCAGATGTTCGTGAC -3 and gyrA-reverse 5-CACCAACGATACGTGCTGAT -3; vraR- forward AAAAGATATCGCCGATGCAG and vraR- reverse ATAACTCTGCCGCGCTTTTTC; sgtB- forward AAACCGCCGAAAAAGAAAAA and sgtB-reverse TCATCCACATTATCGCGTGT; msrA- forward GCAAATGGTGTAGGTAAGACAACT and msrA-reverse ATCATGTGATGTAAACAAAAT; murZ- forward ACGCACACTAAATGGGGAAG and murZ-reverse CCTCAGCAATTAAACCAGCA; lytM- forward ATTAACAGCAGCAGCGATTG and lytM- reverse TGTGCTTGTTGGGTGTTTGT; mntB- forward CCTGGTGTTGCCCTATCATT and mntB-reverse GGCGTCAGGTTTCGTTTTAC.

Inhibition of macromolecular biosynthesis

Macromolecular biosynthesis assays were performed exactly as described previously [31]. Briefly, S. aureus ATCC 292123 was grown in a complete defined medium, and transferred to a round-bottom microwell plate containing radiolabeled precursors [3H]-Leucine; [3H]-Thymine; [3H]-Uridine (Perkin Elmer, Montreal, QC, Canada) or D-[3H]-Alanine (American radiolabeled chemicals, St-Louis, MO, USA), as well as various dilutions of antibiotic agents. Incorporation was allowed to proceed for 45 min (for Leu and D-Ala), or 35 min (for Thy and Uri) at 35°C. The reaction was terminated by transferring the mixtures into pre-chilled trichloroacetic acid (10% final), followed by collection of the precipitated macromolecules on GF/C filter using a dot-blot filtration system. The dried filter was cut and the level of radiolabeled precursor incorporation was determined by liquid scintillation counting. Data represent the average of three independent experiments.

Mouse mastitis model of infection

The mastitis model was previously optimized for experimental therapy [32]. CD-1 lactating mice (Charles River, St-Constant, Canada) were used 12 to 14 days after offspring birth. Pups were removed 1 h before intramammary inoculation, under anesthesia, of both L4 (on the left) and R4 (on the right) abdominal mammary glands with 100 μL of S. aureus Newbould (1 CFU/μL). Glands were treated (intramammary) 4 h after infections with amoxicillin, a cranberry extract or a combination of both. Mice were then sacrificed 14 h post-treatment for mammary gland sampling, homogenization, plating, and bacterial counts. Data represent two independent experiments using several mice and glands in each.
The animal experiments were conducted following the guidelines of the Canadian Council on Animal Care. Protocol 08-FM1 was specifically approved by the institutional ethics committee on animal experimentation of the Faculté des Sciences of Université de Sherbrooke to perform the animal studies included in the present article.

HPLC-MS analysis of cranberry fraction FC111

One milligram aliquots of each dry powdered fraction were suspended in 20% aqueous methanol, 0.1% TFA, at 1 mg/mL, prior to HPLC-MS analysis. This analysis was performed on an Agilent 1100 series LC/MSD SL system (Agilent Technologies, Mississauga, ON), equipped with a quaternary pump, in-line degasser, robotic auto sampler and diode array (DAD) and single quadropole mass spectrometry (SQD) detectors. The separation and characterizations were achieved using a Zorbax Eclipse XDB-C18 (Agilent Technologies) analytical column (4.6 × 150 mm, 5 μm particle size) fitted with a Zorbax Eclipse XDB-C18 analytical guard column (4.6 × 12.5 mm, 5 μm particle size). A tertiary solvent system was used, (A = 0.1% aqueous trifluoroacetic acid; B = water:methanol:trifluoroacetic acid 1:1:0.1; C = acetonitrile), at a flow rate of 0.5 mL/min, with a column temperature of 45°C, and 15 μL sample injection volume , according to the following gradient: Time = 0 min. A:B = 100:0; Time = 2 min. A:B = 85:15; Time = 20 min. A:B = 0:100; Time = 26 min. B = 100% isocratic; Time = 30 min. B:C = 0:100; Time = 33 min. C = 100% isocratic; post time equilibration (3 min.) A = 100%. The entire UV–vis absorption spectrum (190–900 nm) was recorded, while general phenolics (280 nm), anthocyanins (520 nm), and flavonols (360 nm) channels were monitored. Atmospheric pressure electrospray ionization mass spectra in both positive (PIM) and negative (NIM) ion modes (PIM = 150–1400 amu; NIM = 150–2000 amu) were recorded on duplicate injections of the same sample (drying gas flow 10 L/min; nebulizer pressure 30 psig; dry gas temperature 350°C; PIM capillary voltage 3000; NIM capillary voltage 3500). Peak identities were assigned using a combination of UV–vis absorption spectra, MS fragmentation patterns, congruent retention times with commercially available standards, and comparison to relevant cranberry literature [3335].

Statistical analysis

Statistical analyses were carried out with the GraphPad Prism Software (v.5.00). Tests used for the analysis of each experiment are specified in the figure legends.

Results

The NC90 and the PC fraction FC111 are bactericidal and affect the transcription of genes associated with a cell wall stress

The MIC of the cranberry product NC90 against S. aureus ATCC 29213, Newbould and MRSA COL was 2 mg/mL. In an attempt to understand the basis of the growth inhibitory effect of NC90 observed on S. aureus, we studied the modulation of bacterial gene expression for a variety of strains by microarray analyses (Table 1). Exposure of any of the four tested S. aureus strains (ATCC 29213, MRSA N315, SHY97-4320, SHY97-3906) to NC90 up-regulated strongly several genes involved in cell wall biosynthesis, similar to the up-regulation of genes caused by antibiotics known to disrupt peptidoglycan biosynthesis. Indeed, the strong expression of fmt, pbp2, murZ, sgtB, tcaA and vraS/R genes is evidence of a cell wall stress induced by the tested cranberry product NC90 (Table 1). Our data are consistent with the results from other laboratories on the transcriptional profiles obtained by exposure of S. aureus to oxacillin, bacitracin and D-cycloserine [30] or to daptomycin and vancomycin [29] and these similarities are also reported in Table 1. NC90 also up-regulated lytM, encoding a peptidoglycan hydrolase distinctively like daptomycin (Table 1), and down-regulated genes such as spa, mntABC, isdA, hla, and femC.
Table 1
Genes up- and down-regulated for at least two of four S. aureus strains following a 30-min exposure to the cranberry product NC90 (2 mg/mL)
ORF SACOL
Gene name
Gene annotation
Fold expressionafor each strain
     
   
ATCC 29213
MRSA N315
SHY97 4023
SHY97 3906
DAP b
VAN b
OXA b
OBC c
Vra d
Up-regulated genes
         
0263
 
Peptidoglycan hydrolase
15.0
24.5
3.6
9.8
+
=
=
=
 
1066
fmt
Fmt protein
6.8
3.8
2.9
2.0
+
+
+
+
+
1459
 
Methionine sulfoxide reductase
2.3
6.0
−1.5
1.2
=
+
+
+
 
1490
pbp2
Penicillin binding protein 2
2.5
2.8
1.0
1.9
+
+
+
+
+
1777
htrA
Putative serine protease Htra
4.6
8.9
1.0
2.1
+
+
+
=
 
1932
 
Transglycosylase domain protein
8.5
6.8
2.2
2.5
+
=
=
+
+
1942
vraR
DNA-binding response regulator
8.8
10.9
nd
2.7
+
+
+
=
+
1943
vraS
Sensor histidine kinase VraS
14.2
10.5
7.6
4.0
+
+
+
+
+
1944
 
Hypothetical protein
5.1
7.5
1.3
1.4
+
+
+
+
+
2017
groES
Chaperonin
nd
2.2
2.3
2.2
+
+
+
=
 
2116
mur AB
UDP-N-AcGlc-1-carbotransferase
4.0
7.6
2.5
2.6
+
+
+
+
+
2291
 
Staphyloxanthin biosynthesis
6.0
2.2
4.5
3.9
=
 
2352
tcaA
TcaA protein
5.1
6.3
1.1
1.4
+
+
+
+
+
2584
isaA
Immunodominant antigen A
2.1
1.8
2.3
2.1
=
=
=
=
 
Down-regulated genes
         
0095
spa
IgG binding protein
−33.3
−2.0
−37.5
nd
=
=
  
0096
sarS
Accessory regulator
−2.0
−2.9
−2.7
−2.2
  
0136-0150e
capA-O
Capsular polysaccharide
−4.9
nd
−3.1
−1.9
=
  
0317
 
Lipase precursor
−8.6
−6.8
−4.1
−1.7
=
  
451-452e
ahpFC
Alkyl hydroperoxide reductase
−3.4
−3.6
−8.2
−1.2
=
=
  
0679
 
Na+/H+ antiporter, MnhA
−4.5
−10.0
−13.0
−25.0
=
=
=
  
0688-0690e
mntABC
ABC transporter
−43.5
−66.7
−86.7
−91.7
=
=
  
0765-0766e
saeSR
Sensor/Histidine kinase
−1.5
−3.7
−1.5
−3.6
=
=
=
  
1072
folD
THF dehydrogenase
−2.1
−2.6
−2.7
nd
=
=
=
  
1079
purF
amidophosphoribosyltransferase
nd
−10.0
−0.8
−2.6
=
  
1140
isdA
Heme-iron transport
−5.3
−2.1
−2.9
nd
=
=
  
1158-1160e
sdhABC
Succinate dehydrogenase
−5.1
−7.9
−4.5
−3.8
=
  
1173
hla
Alpha-hemolysin
−3.6
−4.3
nd
−2.6
=
=
  
1262-1263e
sucCD
Succinyl-CoA synthetase
−5.6
−3.1
−6.4
−2.3
=
=
=
  
1328
glnR
Glutamine synthetase repressor
−3.7
−6.3
−3.4
−5.3
=
  
1329
femC
Glutamine synthetase FemC
−2.7
−4.2
−3.2
−2.9
=
=
  
1368
katA
Catalase
−3.2
−2.4
−5.2
−2.1
=
+
=
  
1385
acnA
Aconitate hydratase
−3.4
−3.0
−6.3
nd
=
=
=
  
1396
fmtC
FmtC protein
−0.9
−2.4
−2.0
nd
  
1448-1449e
sucAB
2-oxoglutarate dehydrogenase
−8.1
−5.4
−4.8
−4.9
=
=
=
  
1741
icd
Isocitrate dehydrogenase, NADP
−5.6
−2.2
−11.5
−2.5
=
=
+
  
1742
gtlA
Citrate synthase
−6.7
−2.3
−14.3
−2.2
=
=
+
  
1743
 
Amino acid permease
−3.1
−1.2
−4.8
−1.5
=
=
=
  
2055
rsbW
Anti-sigma B factor
−2.6
nd
−1.6
−2.1
=
  
2057
rsbU
Sigma factor B regulator protein
−1.3
−3.1
−0.9
−2.1
=
=
  
2066-2068e
kdpABC
Potassium-transporting ATPase
−3.5
nd
−2.3
−1.7
=
=
=
  
2293
 
NAD/NADP dehydrogenase
−2.0
−2.4
−1.3
nd
=
  
2694
geh
lipase
−27.3
−4.3
−20.0
nd
=
=
=
  
a Data are expressed in log2 ratios of Cy5(cranberry-treated)/Cy3(untreated control); see material and methods.
b Up (+) or down (−) expression of the indicated gene by exposure to daptomycin (DAP), vancomycin (VAN) or oxacillin (OXA), as reported by Muthaiyan et al. [29]; the equal sign (=) indicates genes that were not affected.
c Up (+) or down (−) expression of the indicated gene by exposure to oxacillin (O), bacitracin (B) and D-cycloserine (C) as reported by Utaida et al. [30]; the equal sign (=) indicates genes that were not affected.
d The plus sign (+) indicates genes known to be regulated by the two-component response regulator VraSR following a cell wall stress [42].
e To avoid repetition, the fold modulation of genes arranged in operons is represented as an average for the indicated gene set.
To follow up, extracts from press cakes (PC) were investigated. The MIC of FC111 (lab- and pilot scale extracts) was lower than that of NC90 and represented 1 mg/mL against S. aureus ATCC 29213, Newbould and MRSA COL. Besides, the MIC value for both FC121 and FC131 was higher (3 mg/mL). Since FC111 showed the lowest MIC (best efficiency), its bactericidal effect against S. aureus ATCC 29213 and MRSA COL was evaluated in time-kill experiments. FC111 at 1 mg/mL (MIC) induced more than a 3-log10 reduction of CFU/mL against both strains compared to their respective untreated control cultures after 8 h of incubation and a concentration of 2 X MIC (2 mg/mL) yielded more than a 6-log10 reduction of CFU/mL at 8 h and no detectable CFU after 24 h (data not shown).
Subsequently, we used qPCR to first confirm the transcriptional effects induced in S. aureus ATCC 29213 following exposure to NC90 in DNA array experiments (above) and secondly, to detect similar transcriptional modulations induced by the most active ethanol-extracted PC fraction FC111. Modulation of the same cell wall stress markers (lytM, vraR, sgtB, msrA, murZ and mntB) was indeed detected for both FC111 and NC90, indicating a similar mode of action against S. aureus (Figure 1).

FC111 inhibits cell wall biosynthesis

Whole-cell macromolecular biosynthesis assays were performed to elucidate the mechanism of action of FC111 and to confirm its inhibitory effect on cell-wall biosynthesis. S. aureus ATCC 29213 was treated with several concentrations of the cranberry fraction FC111 or known antibiotics and the percentage of incorporation of radiolabeled precursors into macromolecules was evaluated (Figure 2). All known drugs targeted the expected macromolecular biosynthesis; chloramphenicol, norfloxacin, rifampicin and vancomycin inhibited protein, DNA, RNA and cell wall biosynthesis, respectively. In the presence of 2 (2 mg/ml) and 4 times (4 mg/ml) the MIC of the cranberry fraction FC111, the incorporation of D-[3H]Ala, a precursor of cell wall peptidoglycan, was significantly reduced compared to that observed for precursors of DNA, RNA and proteins (Figure 2E).

In Vitro bactericidal effect of FC111 and β-lactam antibiotic combinations

Since exposure of S. aureus to FC111 induced cell wall stress, we investigated the potential synergy between this cranberry PC fraction with amoxicillin (used for treatment of S. aureus-induced bovine mastitis in veterinary medicine) and oxacillin (used for many clinical indications in humans). Checkerboard assays were performed and a FIC index was determined for each tested combination against S. aureus ATCC 29213 (β-lactam susceptible strain) and MRSA COL (with the mecA/PBP2A-mediated β-lactam resistance). The cranberry fraction FC111 increased the inhibitory activity of amoxicillin and oxacillin against both tested S. aureus strains by triggering up to 512-fold reductions in β-lactam MIC values (Table 2). Combination of FC111, 128 or 256 μg/mL (i.e., 1/8 or 1/4 FC111 MIC, respectively), with either of the β-lactams yielded FIC indices of ≤0.25, for each of the strains tested. These FIC indices clearly showed synergy between FC111 and β-lactams against S. aureus. Data also demonstrated that this synergy can efficiently bypass the mecA-mediated mechanism of β-lactam resistance found in MRSA strain COL.
Table 2
Minimal inhibitory concentrations (MIC) of amoxicillin and oxacillin alone or in combination with increasing concentrations (0 to 256 μg/ml) of the cranberry PC fraction FC111 against S. aureus ATCC 29213 and MRSA COL
S. aureus strains
Antibiotic
MIC of antibiotic in μg/mL in the presence of an increasing concentration of the cranberry fraction FC111, also in μg/mL (fold decrease in antibiotic MIC)a
  
0
32
64
128
256
ATCC 29213
amoxicillin
0.06
0.06 (1×)
0.06 (1×)
0.015 (4×)
0.015 (4×)
MRSA COL
 
512
4 (128×)
4 (128×)
1 (512×)
1 (512×)
ATCC 29213
oxacillin
0.5
0.06 (8×)
0.03 (16×)
0.03 (16×)
0.03 (16×)
MRSA COL
 
512
256 (2×)
128 (4×)
32 (16×)
16 (32×)
a Combination of 128 or 256 μg/mL of FC111 with either antibiotic yielded FIC indices of ≤0.25 against all tested strains.
The synergistic effect arising from the combination of β-lactams and FC111 in checkerboard assays was explored in greater details by using kill kinetic studies. Combination of the cranberry fraction FC111 at its MIC (1 mg/mL) and 1/8 × MIC of amoxicillin induced a strong bactericidal effect (>3 Log10 CFU/mL) against a bovine mastitis strain (S. aureus Newbould, also used in our mastitis model of infection in the mouse [see below]) compared to the bactericidal effect observed with FC111 or amoxicillin alone (Figure 3A). Moreover, the combination of FC111 at its MIC and oxacillin (1/512 × MIC) also showed strong bactericidal effect against S. aureus MRSA COL (Figure 3B).

The FC111-amoxicillin combination improves bacterial clearance in mammary glands

The in vivo relevance of the synergy between the cranberry extract FC111 with β-lactams was determined using a mouse mastitis model. The mice were infected with the bovine strain S. aureus Newbould and treated with FC111, amoxicillin or a combination of both (Figure 4). Compared to the untreated mice, there was no significant change in bacterial loads (CFU/g of gland) when mice were treated with either one of the compounds. However, a significant reduction in bacterial counts (1.8 Log10 CFU/g of gland) was observed using the FC111-amoxicillin combination.

HPLC-MS analysis of cranberry fraction FC111

HPLC-MS was performed on laboratory-scale cranberry fraction FC111, which had the following spectrophotometrically measured [22] classes of chemical compounds per gram of freeze-dried powder: 132.4 (total phenolics), 8.3 (tartaric esters), 9.6 (flavonols) and 23.8 (anthocyanins) mg equivalents of catechin, caffeic acid, quercetin and cyanidin-3-glucoside, respectively. The total phenolics, tartaric esters and flavonols compared well with the composition of the pilot scale sample FC111 [17]. Laboratory- and pilot-scale prepared FC111 provided identical antibacterial activity against S. aureus strains as reported above. HPLC separation of cranberry fraction FC111 constituents was achieved in less than 30 min, using the program described above. A typical chromatographic trace, recorded at 254 nm from laboratory scale FC111 (Figure 5), demonstrates the separation of iridoids, hydroxybenzoic acid, hydroxycinnamic acid, anthocyanin and flavonol components (Table 3). Compounds lacking UV-absorbing chromophores (sugars, small organic acids etc.) were omitted from analysis. In fraction FC111, qualitatively representative of all PC extracts, the principal components were anthocyanins, peaks 21, 24–29, 31, 33 (40%), flavonols, peaks 30–32, 34–44 (25%), iridoids, peaks 2a,b, 3, 16b (22%), and the conjugated glycosides of simple phenolic acids, peaks 4–15, 16a, 17–19 (9%), based on integrated peak areas recorded at 254 nm measured against total absorbance. Absolute quantification of peaks (mass balance) could not be measured, due to lack of analytical standards. Relative abundances between classes of molecules were calculated however, using integral values measured at 254 nm, while specific wavelengths were used to compare individual compounds within a class; 520, 360, and 280 nm for anthocyanins, flavonols and phenolics, respectively (Table 3, peak identities). The primary anthocyanins present were peonidin-3-O-galactoside (peak 28, 43% abundance), cyanidin-3-O-galactoside (peak 24, 18% abundance) and peonidin-3-O-arabinoside (peak 31, 15% abundance) (Table 3, abundances).
Table 3
Laboratory scale cranberry fraction FC111 constituents separated and characterized by HPLC-DAD-MS.
Peak
tR(min)a
λmax (nm)b
MW (Da)c
Putative identification
Relative abundanced
1a,b
4.8
 
192
quinic acid
 
Iridoids
  
2a,b
6.5
235
390
monotropein
18.5 ± 0.78%
3
7.3
235
392
6,7-dihydromonotropein
26.8 ± 0.07%
16b
14.4
235
416
unknown monotropein derivative
54.8 ± 0.99%
    
Total (vs. A254 nm)
22 %
Monophenolic acids
4
8.7
280
220
unknown benzoic acid derivative
3.1 ± 0.51%
5
8.9
280
 
unknown benzoic acid derivative
0.52 ± 0.06%
6
9.7
290
162
unknown benzoic acid derivative
0.78 ± 0.10%
7
9.8
290
 
unknown benzoic acid derivative
1.18 ± 0.11%
8
10.4
275
316
dihydroxybenzoic acid glycoside
3.45 ± 0.29%
9a,b
11.6
285, 320
342
caffeic acid glycoside
3.06 ± 0.45%
10
12.0
275
300
hydroxybenzoic acid glycoside
0.72 ± 0.16%
11
12.3
295, 305
326
coumaric acid glycoside isomer 1
14.04 ± 0.49%
12
12.4
275
238
unknown benzoic acid derivative
1.45 ± 0.049%
13
13.6
315
326
coumaric acid glycoside isomer 2
15.1 ± 0.40%
14
13.8
285, 310
326
coumaric acid glycoside isomer 3
16.1 ± 0.56%
15
14.1
295, 325
 
unknown hydroxycinnamic acid
7.22 ± 0.092%
16a
14.4
280
284
benzoyl-glycoside
5.44 ± 0.89%
17
14.7
285, 330
356
ferulic acid-glycoside
5.59 ± 0.21%
18
15.0
275
 
unknown benzoic acid derivative
13.24 ± 0.13%
19
15.3
280, 330
386
sinapinic acid-glycoside
7.47 ± 0.28%
20a,b
16.3
280
 
unknown benzoic acid derivative
1.50 ± 0.69%
    
Total (vs. A254 nm)
9%
Anthocyanins
21
16.8
525
465
delphinidin-3-O-galactoside
0.40 ± 0.00%
24
18.0
518
449
cyanidin-3-O-galactoside
18.4 ± 0.01%
25
18.2
525
435
delphinidin-3-O-arabinoside
0.60 ± 0.03%
26
19.0
515
433
pelargonidin-3-O-galactoside
0.28 ± 0.00%
27
19.3
520
419
cyanidin-3-O-arabinoside
11.2 ± 0.00%
28
19.8
520
463
peonidin-3-O-galactoside
43.3 ± 0.03%
29
20.4
524
493
malvidin-3-O-galactoside
7.64 ± 0.00%
31
21.1
521
433
peonidin-3-O-arabinoside
15.5 ± 0.01%
33
21.6
530
463
malvidin-3-O-arabinoside
1.79 ± 0.00%
    
Total (vs. A254 nm)
40%
Flavonols
30
20.5
370
450
myricetin-3-O-arabinoside
4.05 ± 0.34%
32
21.3
360
464
quercetin-3-O-galactoside
50.2 ± 0.11%
34
22.0
354
434
quercetin-3-O-xyloside
7.71 ± 0.00%
35
22.3
352
434
quercetin-3-O-arabinopyranoside
3.72 ± 0.02%
36
22.8
354
434
quercetin-3-O-arabinofuranside
13.65 ± 0.12%
37
23.3
352
448
quercetin-3-O-rhamnoside
2.87 ± 0.01%
38
23.6
356
478
isorhamnetin-3-O-galactoside
5.31 ± 0.04%
39
24.0
360
508
syringetin-3-O-galactoside
4.70 ± 0.05%
40
24.7
360
 
unknown flavonol derivative
0.46 ± 0.02%
41
25.0
355
448
isorhamnetin-3-O-arabinoside
1.55 ± 0.01%
42a,b
25.6
355
610
quercetin-3-O-(6”coumaroyl)-galactoside
2.27 ± 0.04%
43
26.1
355
478
syringetin-3-O-arabinoside
2.04 ± 0.04%
44
27.5
356
568
quercetin-3-O-(6” benzoyl)-galactoside
1.48 ± 0.02%
    
Total (vs. A254 nm)
25%
a tR , retention time of peak (measured in minutes).
b λmax, refers to characteristic UV–VIS absorption maxima (nm) pertinent to identification.
c MW, molecular weight (measured in Daltons).
d Relative abundance reported as percentage with associated standard deviation (based on two separate HPLC runs); iridoids calculated vs. 254 nm; monophenolic acids calculated vs. 280 nm; anthocyanins calculated vs. 520 nm; flavonols calculated vs. 360 nm.

Discussion

The outbreak of multidrug resistant bacteria arose from several factors, including the lack of novelty in the pipeline of drug discoveries since the 1980s, and the large and non-adequate administration of antibiotics [7, 36]. To eradicate this problem, explorations of new sources of antimicrobial compounds, and/or finding ways to strengthen the action of well-known antibiotics are needed [31, 37]. For many decades, cranberry juice and extracts have been studied for their antimicrobial potential against bacterial pathogens. Cranberry constituents are known to exert anti-adhesion and antimicrobial activities against several pathogenic bacteria and have been suggested to prevent urinary tract infections caused by uropathogenic P-type Escherichia coli[3840]. However, the mechanisms supporting the diverse effects of cranberry on microbes are poorly understood. In this study, we produced cranberry extracts by mechanical and ethanol extraction, investigated the antibacterial modes of action of these extracts by transcriptional and macromolecular biosynthesis analyses, and assessed their in vitro and in vivo bactericidal activities.
In an attempt to investigate the mode of action of the cranberry product NC90, we initiated the study by performing an exploratory transcriptional analysis by microarray, which yielded the identification of several bacterial genes known to be up-regulated in the presence of cell-wall acting antibiotics, such as oxacillin, vancomycin and daptomycin [29, 30, 41]. Also, the cell wall stress stimulon we observed correlated well to the list of VraS/R-regulated genes known to be up-regulated in response to the inhibition of cell wall biosynthesis [42], as reported in Table 1. Interestingly, the cranberry PC extract FC111 showed a slightly lower MIC than the commercial preparation NC90 against S. aureus, indicating enrichment in some antibacterial compounds in FC111. In addition, qPCR analysis of key cell wall stress markers (vraR/S, sgtB, msrA, murZ) revealed similar gene expression modulations by both NC90 and the fraction FC111, indicating that the growth inhibitory compounds remaining in FC111 should be responsible for the cell wall stress observed following exposure of S. aureus to this extract.
Although oxacillin, vancomycin and daptomycin disrupt cell wall peptidoglycan synthesis, these antibiotics act in different ways [29, 43]. In the present study, it was interesting to observe that NC90 and FC111 also modulated the expression of lytM and the mntABC operon reacting to membrane depolarization, as distinctively reported for daptomycin by Muthaiyan et al. [29]. This may indicate that NC90 and the cranberry extract FC111 induce S. aureus membrane depolarization, as that observed after exposure to daptomycin. The gene modulations induced by cranberry also support the S. aureus cell disruption reported by Wu et al. [20], while, scanning electron microscopy of MRSA after treatment with cranberry proanthocyanidins induced negligible effect on cell morphology [44].
The action of our cranberry extract on cell wall biosynthesis was also confirmed by macromolecular biosynthesis assays in which incorporation D-Ala into cell wall materials was most affected. Hence, it was therefore tempting to conduct synergy assays with other cell-wall active antibiotics. Because β-lactams are widely used in human and veterinary medicine and because their activity is often impaired by bacterial mechanisms of resistance such as the presence of β-lactamases or the mecA gene in MRSA strains, we estimated that such a class of antibiotic compounds may greatly benefit from the action of cranberry in a variety of clinical applications. Our results showed that the combination of FC111 and amoxicillin or oxacillin used at sub-MICs, is highly bactericidal against either β-lactam-susceptible or -resistant MRSA strains. Moreover, this synergy was proven effective in a murine model of S. aureus-induced mastitis.
Resistance is part of the microbial evolution process and the use of antibiotics in human or animals applies a selective pressure favoring resistance to emerge. We did indeed report the presence of multi-antibiotic-resistant bacteria in animal food production [45, 46]. In order to reduce antibiotic use, which could help break down emergence of antibiotic resistance in conventional and organic animal production, several alternatives to antibiotics have been investigated although none of these alternatives was proven to be as efficient as antibiotics [47, 48]. We previously suggested that cranberry fruit derivatives could be developed to improve health and on-farm food safety while reducing the use of antibiotics as growth promoters [19]. It was recently suggested that fruit pomace can be utilized as a good source of inexpensive antioxidants for improving human health and reducing the risks of some chronic diseases [49]. Recently, we showed that our FC111 fraction from cranberry pomace (press cake) is an excellent natural polyphenolics product with increased antioxidant and vasorelaxant benefits [17]. In the present study, we demonstrated that this FC111 fraction may be developed as a viable alternative to traditional antibiotics or at least to significantly potentiate their activities against multidrug resistant bacteria such as MRSA, and thus, to significantly reduce the amounts of antibiotics required.
The cranberry fruit is rich in polyphenols, specifically anthocyanins, flavonols and flavan3-ols, which often form oligomeric and polymeric structures, along with lesser amounts of benzoic acid derivatives. These natural compounds in cranberry are often collectively referred to as tannins, which are found in abundance among many plants including berries, leaves, bark and roots. Tannins have many biological activities and flavonoids, including anthocyanins and proanthocyanidins, are believed to be the major antimicrobial components [50]. Here, the relative abundances of constituents from fraction FC111 are described in Table 3. The primary anthocyanins present were peonidin-3-O-galactoside, cyanidin-3-O-galactoside and peonidin-3-O-arabinoside. Malvidin-3-O-galactoside and 3-O-arabinoside were also present, consistent with previously reported literature for both fresh cranberry fruit and juice extracts [33, 34]. The dominant flavonol was quercetin-3-O-galactoside (peak 32, 50% abundance), followed by three different quercetin-3-O-pentosides (peaks 34, 35, 36), totaling 25% abundance). While commercial standards were not available for the absolute confirmation of these pentosides, they have been tentatively identified as quercetin-3-O-xyloside, quercetin-3-O-arabinofuranoside, and querecetin-3-O-arabinopyranoside, as previously reported by Borges et al. [33]. Additionally, numerous early eluting peaks (8–16 min) were detected, with absorption wavelength maxima characteristic of benzoic acids (λmax ~280 nm) and hydroxycinnamic acids (λmax ~ 315 nm) (Table 3), also consistent with previously reported literature [33, 34]. Characteristic mass spectra for both parent and fragment ions indicates a number of these simple phenolic acids are linked to hexose sugars, but the absolute identity, galactose versus glucose sugar, or exact O-linkage position could not be determined using HPLC-MS methods alone.
From our analysis of the constituents of laboratory-scale fraction FC111, it is unclear, at this point, whether the observed antibacterial activity stems from iridoids, phenolics or flavonoid components, with further isolation and characterization remaining an active area of research. However, the mechanisms of action of our FC111 fraction seem not to be related to its acidic constituents, which negatively impact bacterial proteins and DNA/RNA syntheses [51]. Bactericidal activity of lab-prepared cranberry proanthocyanidins has been reported against MRSA [44]. Proanthocyanidin peaks could not be conclusively identified, based upon the HPLC-MS-conditions used. It is possible that the ethanolic PC extraction may not have been optimal for the solubilization of proanthocyanidins, which are generally extracted with more apolar solvents such as acetone. Given their low (essentially non-abundance) in the extracts studied herein, proanthocyanidins are not expected to play a major role in the observed biological effects, unless extraordinarily active at minute concentrations. Demonstrating novel antibacterial activity from cranberries not associated with proanthocyanidin components is especially exciting, and warrants further investigation.

Conclusions

Our study explored the mechanism of action of cranberry on S. aureus and revealed an antibacterial action associated with the disruption of cell wall biosynthesis similar to other known cell-wall acting antibiotics. Moreover, our results showed the potential therapeutic use of a combination of β-lactams and an easily prepared cranberry extract against S. aureus infections such as bovine mastitis.

Acknowledgements

This work was supported by research grant 89758–2010 from the Natural Sciences and Engineering Research Council of Canada (NSERC) to FM and by financial support (#1381) from Agriculture and Agri-Food Canada to MSD. We thank Decas Botanical and V. Brookes (PARC, Agassiz) for providing the cranberry extract NC90 and fresh cranberry fruits. We acknowledge technical supports by A. Campbell, E. Fan and K. Jassmann.
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://​creativecommons.​org/​licenses/​by/​2.​0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

The authors declare that they have no competing interests. Also note that Decas Botanical Synergies, the manufacturers of NC90, played no role in the design, implementation, analysis, or financing of this study.

Authors’ contributions

SB, EB, MG, GB, HR, JH and JM carried out the experiments. MSD, BDO, SB, EB, MG, JH and FM designed and conceived the study. MSD, DBO, SB, JH and FM wrote the paper. All authors read and approved the final manuscript.
Literatur
1.
Zurück zum Zitat Archer GL: Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis. 1998, 26: 1179-1181. 10.1086/520289.CrossRefPubMed Archer GL: Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis. 1998, 26: 1179-1181. 10.1086/520289.CrossRefPubMed
2.
Zurück zum Zitat Seo KS, Bohach GA: Staphylococcus aureus. Food Microbiology: Fundamentals and Frontiers. Edited by: Doyle MP, Beuchat LR. 2007, Washington, DC, USA: ASM Press, 493-518. 3CrossRef Seo KS, Bohach GA: Staphylococcus aureus. Food Microbiology: Fundamentals and Frontiers. Edited by: Doyle MP, Beuchat LR. 2007, Washington, DC, USA: ASM Press, 493-518. 3CrossRef
3.
Zurück zum Zitat Reyher KK, Dufour S, Barkema HW, Des Coteaux L, Devries TJ, Dohoo IR, Keefe GP, Roy JP, Scholl DT: The National Cohort of Dairy Farms - a data collection platform for mastitis research in Canada. J Dairy Sci. 2011, 94: 1616-1626. 10.3168/jds.2010-3180.CrossRefPubMed Reyher KK, Dufour S, Barkema HW, Des Coteaux L, Devries TJ, Dohoo IR, Keefe GP, Roy JP, Scholl DT: The National Cohort of Dairy Farms - a data collection platform for mastitis research in Canada. J Dairy Sci. 2011, 94: 1616-1626. 10.3168/jds.2010-3180.CrossRefPubMed
4.
Zurück zum Zitat Jordan FTW: Poultry Diseases. 2008, Philadelphia, PA USA: Saunder Elsevir Lte, 191-195. 6 Jordan FTW: Poultry Diseases. 2008, Philadelphia, PA USA: Saunder Elsevir Lte, 191-195. 6
5.
Zurück zum Zitat De Kimpe SJ, Thiemermann C, Vane JR: Role for intracellular platelet-activating factor in the circulatory failure in a model of gram-positive shock. Br J Pharmacol. 1995, 116: 3191-3198. 10.1111/j.1476-5381.1995.tb15123.x.CrossRefPubMedPubMedCentral De Kimpe SJ, Thiemermann C, Vane JR: Role for intracellular platelet-activating factor in the circulatory failure in a model of gram-positive shock. Br J Pharmacol. 1995, 116: 3191-3198. 10.1111/j.1476-5381.1995.tb15123.x.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Donlan RM: Biofilms: microbial life on surfaces. Emerg Infect Dis. 2002, 89: 881-890.CrossRef Donlan RM: Biofilms: microbial life on surfaces. Emerg Infect Dis. 2002, 89: 881-890.CrossRef
8.
Zurück zum Zitat Zechini B, Versace I: Inhibitors of multidrug resistant efflux systems in bacteria. Recent Pat Antiinfect Drug Discov. 2009, 41: 37-50.CrossRef Zechini B, Versace I: Inhibitors of multidrug resistant efflux systems in bacteria. Recent Pat Antiinfect Drug Discov. 2009, 41: 37-50.CrossRef
9.
Zurück zum Zitat Faria NA, Oliveira DC, Westh H, Monnet DL, Larsen AR, Skov R, de Lencastre H: Epidemiology of emerging methicillin-resistant Staphylococcus aureus (MRSA) in Denmark: a nationwide study in a country with low prevalence of MRSA infection. J Clin Microbiol. 2005, 43: 1836-1842. 10.1128/JCM.43.4.1836-1842.2005.CrossRefPubMedPubMedCentral Faria NA, Oliveira DC, Westh H, Monnet DL, Larsen AR, Skov R, de Lencastre H: Epidemiology of emerging methicillin-resistant Staphylococcus aureus (MRSA) in Denmark: a nationwide study in a country with low prevalence of MRSA infection. J Clin Microbiol. 2005, 43: 1836-1842. 10.1128/JCM.43.4.1836-1842.2005.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Chambers HF, DeLeo FR: Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009, 7: 629-641. 10.1038/nrmicro2200.CrossRefPubMedPubMedCentral Chambers HF, DeLeo FR: Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009, 7: 629-641. 10.1038/nrmicro2200.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Khanna T, Friendship R, Dewey C, Weese SJ: Methicillin resistant Staphylococcus aureus colonization in pigs and pig farmers. Vet Microb. 2008, 128: 298-303. 10.1016/j.vetmic.2007.10.006.CrossRef Khanna T, Friendship R, Dewey C, Weese SJ: Methicillin resistant Staphylococcus aureus colonization in pigs and pig farmers. Vet Microb. 2008, 128: 298-303. 10.1016/j.vetmic.2007.10.006.CrossRef
12.
Zurück zum Zitat van Loo I, Huijsdens X, Tiemersma E, de Neeling A, van de Sande-Bruinsma N, Beaujean D, Voss A, Kluytmans J: Emergence of methicillin-resistant Staphylococcus aureus of animal origin in humans. Emerg Infect Dis. 2007, 13: 1834-1838. 10.3201/eid1312.070384.CrossRefPubMedPubMedCentral van Loo I, Huijsdens X, Tiemersma E, de Neeling A, van de Sande-Bruinsma N, Beaujean D, Voss A, Kluytmans J: Emergence of methicillin-resistant Staphylococcus aureus of animal origin in humans. Emerg Infect Dis. 2007, 13: 1834-1838. 10.3201/eid1312.070384.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Garcia-Alvarez L, Holden MT, Lindsay H, Webb CR, Brown DF, Curran MD, Walpole E, Brooks K, Pickard DJ, Teale C, Parkhill J, Bentley SD, Edwards GF, Girvan EK, Kearns AM, Pichon B, Hill RL, Larsen AR, Skov RL, Peacock SJ, Maskell DJ, Holmes MA: Methicillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study. Lancet Infect Dis. 2011, 11: 595-603. 10.1016/S1473-3099(11)70126-8.CrossRefPubMedPubMedCentral Garcia-Alvarez L, Holden MT, Lindsay H, Webb CR, Brown DF, Curran MD, Walpole E, Brooks K, Pickard DJ, Teale C, Parkhill J, Bentley SD, Edwards GF, Girvan EK, Kearns AM, Pichon B, Hill RL, Larsen AR, Skov RL, Peacock SJ, Maskell DJ, Holmes MA: Methicillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study. Lancet Infect Dis. 2011, 11: 595-603. 10.1016/S1473-3099(11)70126-8.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Haran KP, Godden SM, Boxrud D, Jawahir S, Bender JB, Sreevatsan S: Prevalence and characterization of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, isolated from bulk tank milk from Minnesota dairy farms. J Clin Microbiol. 2012, 50: 688-695. 10.1128/JCM.05214-11.CrossRefPubMedPubMedCentral Haran KP, Godden SM, Boxrud D, Jawahir S, Bender JB, Sreevatsan S: Prevalence and characterization of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, isolated from bulk tank milk from Minnesota dairy farms. J Clin Microbiol. 2012, 50: 688-695. 10.1128/JCM.05214-11.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Petinaki E, Spiliopoulou I: Methicillin-resistant Staphylococcus aureus among companion and food-chain animals: impact of human contacts. Clin Microbiol Infect. 2012, 18: 626-634. 10.1111/j.1469-0691.2012.03881.x.CrossRefPubMed Petinaki E, Spiliopoulou I: Methicillin-resistant Staphylococcus aureus among companion and food-chain animals: impact of human contacts. Clin Microbiol Infect. 2012, 18: 626-634. 10.1111/j.1469-0691.2012.03881.x.CrossRefPubMed
16.
Zurück zum Zitat Côté J, Caillet S, Doyon G, Dussault D, Sylvain J, Lacroix M: Antimicrobial effect of cranberry juice and extracts. Food Control. 2011, 22: 1413-1418. 10.1016/j.foodcont.2011.02.024.CrossRef Côté J, Caillet S, Doyon G, Dussault D, Sylvain J, Lacroix M: Antimicrobial effect of cranberry juice and extracts. Food Control. 2011, 22: 1413-1418. 10.1016/j.foodcont.2011.02.024.CrossRef
17.
Zurück zum Zitat Harrison JE, Oomah BD, Diarra MS, Ibarra-Alvarado C: Bioactivities of pilot-scale extracted cranberry juice and pomace. J Food Process Preserv. 2012, 10.1111/j.1745-4549.2011.00655.x. Harrison JE, Oomah BD, Diarra MS, Ibarra-Alvarado C: Bioactivities of pilot-scale extracted cranberry juice and pomace. J Food Process Preserv. 2012, 10.1111/j.1745-4549.2011.00655.x.
18.
Zurück zum Zitat Leitão DPS, Polizello ACM, Ito IY, Spadaro ACC: Antibacterial screening of anthocyanic and proanthocyanic fractions from cranberry juice. J Med Food. 2005, 8: 36-40. 10.1089/jmf.2005.8.36.CrossRefPubMed Leitão DPS, Polizello ACM, Ito IY, Spadaro ACC: Antibacterial screening of anthocyanic and proanthocyanic fractions from cranberry juice. J Med Food. 2005, 8: 36-40. 10.1089/jmf.2005.8.36.CrossRefPubMed
19.
Zurück zum Zitat Leusink G, Rempel H, Skura B, Berkyto M, White W, Yang Y, Rhee J-Y, Xuan SY, Chiu S, Silversides F, Fitzpatrick S, Diarra MS: Growth performance, meat quality and gut microflora of broiler chickens fed with cranberry extract. Poult Sci. 2010, 89: 1514-1523. 10.3382/ps.2009-00364.CrossRefPubMed Leusink G, Rempel H, Skura B, Berkyto M, White W, Yang Y, Rhee J-Y, Xuan SY, Chiu S, Silversides F, Fitzpatrick S, Diarra MS: Growth performance, meat quality and gut microflora of broiler chickens fed with cranberry extract. Poult Sci. 2010, 89: 1514-1523. 10.3382/ps.2009-00364.CrossRefPubMed
20.
Zurück zum Zitat Wu VC, Qiu X, Bushway A, Harper L: Antibacterial effects of American cranberry (Vaccinium macrocarpon) concentrate on foodborne pathogens. LWT - Food Sci Technol. 2008, 41: 1834-1841. 10.1016/j.lwt.2008.01.001.CrossRef Wu VC, Qiu X, Bushway A, Harper L: Antibacterial effects of American cranberry (Vaccinium macrocarpon) concentrate on foodborne pathogens. LWT - Food Sci Technol. 2008, 41: 1834-1841. 10.1016/j.lwt.2008.01.001.CrossRef
21.
Zurück zum Zitat Diarra MS, Petitclerc D, Lacasse P: Response of Staphylococcus aureus isolated from bovine mastitis to exogenous iron sources. J Dairy Sci. 2002, 85: 2141-2148. 10.3168/jds.S0022-0302(02)74292-6.CrossRefPubMed Diarra MS, Petitclerc D, Lacasse P: Response of Staphylococcus aureus isolated from bovine mastitis to exogenous iron sources. J Dairy Sci. 2002, 85: 2141-2148. 10.3168/jds.S0022-0302(02)74292-6.CrossRefPubMed
22.
Zurück zum Zitat Oomah BD, Tiger N, Olson M, Balasubramanian P: Phenolics and antioxidative activities in narrow-leafed lupins (Lupinus angustifolius L.). Plant Foods Hum Nutr. 2006, 61: 91-97.CrossRefPubMed Oomah BD, Tiger N, Olson M, Balasubramanian P: Phenolics and antioxidative activities in narrow-leafed lupins (Lupinus angustifolius L.). Plant Foods Hum Nutr. 2006, 61: 91-97.CrossRefPubMed
23.
Zurück zum Zitat Oomah BD, Blanchard C, Balasubramanian P: Phytic acid, phytase, minerals, and antioxidant activity in Canadian dry bean (Phaseolus vulgaris L.) cultivars. J Agric Food Chem. 2008, 56: 11312-11319. 10.1021/jf801661j.CrossRefPubMed Oomah BD, Blanchard C, Balasubramanian P: Phytic acid, phytase, minerals, and antioxidant activity in Canadian dry bean (Phaseolus vulgaris L.) cultivars. J Agric Food Chem. 2008, 56: 11312-11319. 10.1021/jf801661j.CrossRefPubMed
24.
Zurück zum Zitat Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing, Twenty-First Informational Supplement M100-S21. 2011, Wayne, PA, USA: CLSI Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing, Twenty-First Informational Supplement M100-S21. 2011, Wayne, PA, USA: CLSI
25.
Zurück zum Zitat Eliopoulos GM, Moellering RC: Antimicrobial combinations. Antibiotics in Laboratory Medicine. Edited by: Lorian V. 1996, Baltimore, MD: Williams and Wilkins, 330-336. Eliopoulos GM, Moellering RC: Antimicrobial combinations. Antibiotics in Laboratory Medicine. Edited by: Lorian V. 1996, Baltimore, MD: Williams and Wilkins, 330-336.
26.
Zurück zum Zitat Odds FC: Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003, 52: 1-10.1093/jac/dkg301.CrossRefPubMed Odds FC: Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003, 52: 1-10.1093/jac/dkg301.CrossRefPubMed
27.
Zurück zum Zitat Allard M, Moisan H, Brouillette É, Gervais AL, Jacques M, Lacasse P, Diarra MS, Malouin F: Transcriptional modulation of some Staphylococcus aureus iron-regulated genes during growth in vitro and in a tissue cage model in vivo. Microb Infect. 2006, 8: 1679-1690. 10.1016/j.micinf.2006.01.022.CrossRef Allard M, Moisan H, Brouillette É, Gervais AL, Jacques M, Lacasse P, Diarra MS, Malouin F: Transcriptional modulation of some Staphylococcus aureus iron-regulated genes during growth in vitro and in a tissue cage model in vivo. Microb Infect. 2006, 8: 1679-1690. 10.1016/j.micinf.2006.01.022.CrossRef
28.
Zurück zum Zitat Pruneau M, Mitchell G, Moisan H, Dumont-Blanchette É, Jacob CL, Malouin F: Transcriptional analysis of antibiotic resistance and virulence genes in multi-resistant hospital acquired MRSA. FEMS Immunol Med Microbiol. 2011, 63: 54-64. 10.1111/j.1574-695X.2011.00830.x.CrossRefPubMed Pruneau M, Mitchell G, Moisan H, Dumont-Blanchette É, Jacob CL, Malouin F: Transcriptional analysis of antibiotic resistance and virulence genes in multi-resistant hospital acquired MRSA. FEMS Immunol Med Microbiol. 2011, 63: 54-64. 10.1111/j.1574-695X.2011.00830.x.CrossRefPubMed
29.
Zurück zum Zitat Muthaiyan A, Silverman JA, Jayaswal RK, Wilkinson BJ: Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrob Agents Chemother. 2008, 52: 980-990. 10.1128/AAC.01121-07.CrossRefPubMed Muthaiyan A, Silverman JA, Jayaswal RK, Wilkinson BJ: Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrob Agents Chemother. 2008, 52: 980-990. 10.1128/AAC.01121-07.CrossRefPubMed
30.
Zurück zum Zitat Utaida S, Dunman PM, Macapagal D, Murphy E, Projan SJ, Singh VK, Jayaswal RK, Wilkinson BJ: Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. Microbiology. 2003, 149: 2719-2732. 10.1099/mic.0.26426-0.CrossRefPubMed Utaida S, Dunman PM, Macapagal D, Murphy E, Projan SJ, Singh VK, Jayaswal RK, Wilkinson BJ: Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. Microbiology. 2003, 149: 2719-2732. 10.1099/mic.0.26426-0.CrossRefPubMed
31.
Zurück zum Zitat Mitchell G, Gattuso M, Grondin G, Marsault É, Bouarab K, Malouin F: Tomatidine inhibits replication of Staphylococcus aureus small-colony variants in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother. 2011, 55: 1937-1945. 10.1128/AAC.01468-10.CrossRefPubMedPubMedCentral Mitchell G, Gattuso M, Grondin G, Marsault É, Bouarab K, Malouin F: Tomatidine inhibits replication of Staphylococcus aureus small-colony variants in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother. 2011, 55: 1937-1945. 10.1128/AAC.01468-10.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Brouillette E, Grondin G, Lefebvre C, Talbot BG, Malouin F: Mouse mastitis model of infection for antimicrobial compound efficacy studies against intracellular and extracellular forms of Staphylococcus aureus. Vet Microbiol. 2004, 101: 253-262. 10.1016/j.vetmic.2004.04.008.CrossRefPubMed Brouillette E, Grondin G, Lefebvre C, Talbot BG, Malouin F: Mouse mastitis model of infection for antimicrobial compound efficacy studies against intracellular and extracellular forms of Staphylococcus aureus. Vet Microbiol. 2004, 101: 253-262. 10.1016/j.vetmic.2004.04.008.CrossRefPubMed
33.
Zurück zum Zitat Borges G, Degeneve A, Mullen WP, Crozier A: Identification of flavonoid and phenolic antioxidants in black currants, blueberries, raspberries, red currants, and cranberries. J Agric Food Chem. 2010, 58: 3901-3909. 10.1021/jf902263n.CrossRefPubMed Borges G, Degeneve A, Mullen WP, Crozier A: Identification of flavonoid and phenolic antioxidants in black currants, blueberries, raspberries, red currants, and cranberries. J Agric Food Chem. 2010, 58: 3901-3909. 10.1021/jf902263n.CrossRefPubMed
34.
Zurück zum Zitat Singh AP, Wilson T, Kalk AJ, Cheong J, Vorsa N: Isolation of specific cranberry flavonoids for biological activity assessment. Food Chem. 2009, 116: 963-968. 10.1016/j.foodchem.2009.03.062.CrossRefPubMedPubMedCentral Singh AP, Wilson T, Kalk AJ, Cheong J, Vorsa N: Isolation of specific cranberry flavonoids for biological activity assessment. Food Chem. 2009, 116: 963-968. 10.1016/j.foodchem.2009.03.062.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Viskelis P, Rubinskiene M, Jasutiene I, Sarkinas A, Daubaras R, Cesoniene L: Anthocyanins, antioxidative, and antimicrobial properties of American cranberry (Vaccinium macrocarpon Ait.) and their press cakes. J Food Sci. 2009, 74: C157-61. 10.1111/j.1750-3841.2009.01066.x.CrossRefPubMed Viskelis P, Rubinskiene M, Jasutiene I, Sarkinas A, Daubaras R, Cesoniene L: Anthocyanins, antioxidative, and antimicrobial properties of American cranberry (Vaccinium macrocarpon Ait.) and their press cakes. J Food Sci. 2009, 74: C157-61. 10.1111/j.1750-3841.2009.01066.x.CrossRefPubMed
36.
Zurück zum Zitat Coates A, Halls G, Hu Y: Novel classes of antibiotics or more of the same?. Br J Pharmacol. 2011, 163: 184-194. 10.1111/j.1476-5381.2011.01250.x.CrossRefPubMedPubMedCentral Coates A, Halls G, Hu Y: Novel classes of antibiotics or more of the same?. Br J Pharmacol. 2011, 163: 184-194. 10.1111/j.1476-5381.2011.01250.x.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat González-Lamothe R, Mitchell G, Gattuso M, Diarra MS, Malouin F, Bouarab K: Plant antimicrobial agents and their effects on plant and human pathogens. Int J Molecul Sci. 2009, 10: 3400-3419. 10.3390/ijms10083400.CrossRef González-Lamothe R, Mitchell G, Gattuso M, Diarra MS, Malouin F, Bouarab K: Plant antimicrobial agents and their effects on plant and human pathogens. Int J Molecul Sci. 2009, 10: 3400-3419. 10.3390/ijms10083400.CrossRef
38.
Zurück zum Zitat Cimolai N, Cimolai T: The cranberry and the urinary tract. Eur J Clin Microbiol Infect Dis. 2007, 26: 767-776. 10.1007/s10096-007-0379-0.CrossRefPubMed Cimolai N, Cimolai T: The cranberry and the urinary tract. Eur J Clin Microbiol Infect Dis. 2007, 26: 767-776. 10.1007/s10096-007-0379-0.CrossRefPubMed
39.
Zurück zum Zitat Foo LY, Lu Y, Howell AB, Vorsa N: A-Type proanthocyanidin trimers from cranberry that inhibit adherence of uropathogenic P-fimbriated Escherichia coli. J Nat Prod. 2000, 63: 1225-1228. 10.1021/np000128u.CrossRefPubMed Foo LY, Lu Y, Howell AB, Vorsa N: A-Type proanthocyanidin trimers from cranberry that inhibit adherence of uropathogenic P-fimbriated Escherichia coli. J Nat Prod. 2000, 63: 1225-1228. 10.1021/np000128u.CrossRefPubMed
40.
Zurück zum Zitat Howell AB: Bioactive compounds in cranberries and their role in prevention of urinary tract infections. Mol Nutr Food Res. 2007, 51: 732-737. 10.1002/mnfr.200700038.CrossRefPubMed Howell AB: Bioactive compounds in cranberries and their role in prevention of urinary tract infections. Mol Nutr Food Res. 2007, 51: 732-737. 10.1002/mnfr.200700038.CrossRefPubMed
41.
Zurück zum Zitat Singh VK, Jayaswal RK, Wilkinson BJ: Cell wall-active antibiotic induced proteins of Staphylococcus aureus identified using a proteomic approach. FEMS Microbiol Lett. 2001, 199: 79-84.PubMed Singh VK, Jayaswal RK, Wilkinson BJ: Cell wall-active antibiotic induced proteins of Staphylococcus aureus identified using a proteomic approach. FEMS Microbiol Lett. 2001, 199: 79-84.PubMed
42.
Zurück zum Zitat Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K: Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol Microbiol. 2003, 49: 807-821.CrossRefPubMed Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K: Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol Microbiol. 2003, 49: 807-821.CrossRefPubMed
43.
Zurück zum Zitat Tomasz A: The Staphylococcal Cell Wall. Gram Positive Pathogens. Edited by: Fishetti VA. 2006, Washington, DC. USA: ASM Press, 443-455. 2CrossRef Tomasz A: The Staphylococcal Cell Wall. Gram Positive Pathogens. Edited by: Fishetti VA. 2006, Washington, DC. USA: ASM Press, 443-455. 2CrossRef
44.
Zurück zum Zitat Su X, Howell AB, D’Souza DH: Antibacterial effects of plant-derived extracts on methicillin-resistant Staphylococcus aureus. Foodborn Pathog Dis. 2012, 9: 573-578. 10.1089/fpd.2011.1046.CrossRef Su X, Howell AB, D’Souza DH: Antibacterial effects of plant-derived extracts on methicillin-resistant Staphylococcus aureus. Foodborn Pathog Dis. 2012, 9: 573-578. 10.1089/fpd.2011.1046.CrossRef
45.
Zurück zum Zitat Diarra MS, Rempel H, Champagne J, Masson L, Pritchard J, Topp E: Distribution of antimicrobial resistance and virulence genes in Enterococcus spp: characterization of isolates from broiler chickens. Appl Environ Microbiol. 2010, 76: 8033-8043. 10.1128/AEM.01545-10.CrossRefPubMedPubMedCentral Diarra MS, Rempel H, Champagne J, Masson L, Pritchard J, Topp E: Distribution of antimicrobial resistance and virulence genes in Enterococcus spp: characterization of isolates from broiler chickens. Appl Environ Microbiol. 2010, 76: 8033-8043. 10.1128/AEM.01545-10.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Diarrassouba F, Diarra MS, Bach S, Delaquis P, Pritchard J, Topp E, Skura BJ: Antibiotic resistance and virulence genes in commensal Escherichia coli and Salmonella isolated from commercial broiler chicken farms. J Food Prot. 2007, 70: 1316-1327.PubMed Diarrassouba F, Diarra MS, Bach S, Delaquis P, Pritchard J, Topp E, Skura BJ: Antibiotic resistance and virulence genes in commensal Escherichia coli and Salmonella isolated from commercial broiler chicken farms. J Food Prot. 2007, 70: 1316-1327.PubMed
47.
Zurück zum Zitat Dahiya JP, Wilkie DC, Van Kessel AG, Drew MD: Potential strategies for controlling necrotic enteritis in broiler chickens in post-antibiotic era. Anim Feed Sci Technol. 2006, 129: 60-88. 10.1016/j.anifeedsci.2005.12.003.CrossRef Dahiya JP, Wilkie DC, Van Kessel AG, Drew MD: Potential strategies for controlling necrotic enteritis in broiler chickens in post-antibiotic era. Anim Feed Sci Technol. 2006, 129: 60-88. 10.1016/j.anifeedsci.2005.12.003.CrossRef
48.
Zurück zum Zitat Jacob J, Pescatore A:Gut Health and Organic Acids, Antimicrobial Peptides, and Botanicals as Natural Feed Additives. Organic Meat Production and Processing. Edited by: Ricke SC, Van Loo EJ, Johnson MG, O'Bryan CA. 2012, Oxford, UK: Wiley-Blackwell, 351-378. 10.1002/9781118229088.ch21.CrossRef Jacob J, Pescatore A:Gut Health and Organic Acids, Antimicrobial Peptides, and Botanicals as Natural Feed Additives. Organic Meat Production and Processing. Edited by: Ricke SC, Van Loo EJ, Johnson MG, O'Bryan CA. 2012, Oxford, UK: Wiley-Blackwell, 351-378. 10.1002/9781118229088.ch21.CrossRef
49.
Zurück zum Zitat Tow WW, Premier R, Jing H, Ajlouni S: Antioxidant and antiproliferation effects of extractable and nonextractable polyphenols isolated from apple waste using different extraction methods. J Food Sci. 2011, 76: T163-T172. 10.1111/j.1750-3841.2011.02314.x.CrossRefPubMed Tow WW, Premier R, Jing H, Ajlouni S: Antioxidant and antiproliferation effects of extractable and nonextractable polyphenols isolated from apple waste using different extraction methods. J Food Sci. 2011, 76: T163-T172. 10.1111/j.1750-3841.2011.02314.x.CrossRefPubMed
50.
Zurück zum Zitat Puupponen-Pimiä R, Nohynek L, Meier C, Kähkönen M, Heinonen M, Hopia A, Oksman-Caldentey K: Antimicrobial properties of phenolic compounds from berries. J Appl Microbiol. 2001, 90: 494-507. 10.1046/j.1365-2672.2001.01271.x.CrossRefPubMed Puupponen-Pimiä R, Nohynek L, Meier C, Kähkönen M, Heinonen M, Hopia A, Oksman-Caldentey K: Antimicrobial properties of phenolic compounds from berries. J Appl Microbiol. 2001, 90: 494-507. 10.1046/j.1365-2672.2001.01271.x.CrossRefPubMed
51.
Zurück zum Zitat Taylor M, Joerger R, Palou E, López-Malo A, Avila-Sosa R, Calix-Lara T: Eds S. C. Ricke, E. J. Van Loo, M. G. Johnson. Organic Meat Production and Processing. Edited by: Ricke SC, Van Loo EJ, Johnson MG, O'Bryan CA. 2012, Oxford, UK: Wiley-Blackwell, 211-237. 10.1002/9781118229088.ch13.CrossRef Taylor M, Joerger R, Palou E, López-Malo A, Avila-Sosa R, Calix-Lara T: Eds S. C. Ricke, E. J. Van Loo, M. G. Johnson. Organic Meat Production and Processing. Edited by: Ricke SC, Van Loo EJ, Johnson MG, O'Bryan CA. 2012, Oxford, UK: Wiley-Blackwell, 211-237. 10.1002/9781118229088.ch13.CrossRef
Metadaten
Titel
In vitro and in vivo antibacterial activities of cranberry press cake extracts alone or in combination with β-lactams against Staphylococcus aureus
verfasst von
Moussa S Diarra
Glenn Block
Heidi Rempel
B Dave Oomah
Judy Harrison
Jason McCallum
Simon Boulanger
Éric Brouillette
Mariza Gattuso
François Malouin
Publikationsdatum
01.12.2013
Verlag
BioMed Central
Erschienen in
BMC Complementary Medicine and Therapies / Ausgabe 1/2013
Elektronische ISSN: 2662-7671
DOI
https://doi.org/10.1186/1472-6882-13-90

Weitere Artikel der Ausgabe 1/2013

BMC Complementary Medicine and Therapies 1/2013 Zur Ausgabe